Inovio reports preliminary Q2 2026 cash balance of $36.7M

INOVIO PHARMACEUTICALS, INC.

Cash and cash equivalents estimated at $36.7 million as of June 30, 2026.
Preliminary unaudited data subject to completion of financial closing procedures.
No other financial results or guidance provided in the filing.

item 2.02

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-323628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.